Loading…
Ypsomed completed the sale of its pen needle and blood glucose monitoring businesses to Medical Technology and Devices (MTD). The deal was first announced in March 2024, and Ypsomed will transition production equipment to MTD by mid-2025.
Ypsomed has signed an agreement to transfer its pen needle and blood glucose monitoring systems businesses to Medical Technology and Devices S.p.A. (MTD). The businesses had sales of CHF 52 million in FY 2022/23.
Standex International agreed to sell its Procon Pumps business to Investindustrial at an enterprise value of $75 million, subject to post-closing adjustments. The transaction was expected to close in February 2023.